DE20115218U1 - Amid-Derivat von Amlodipin - Google Patents
Amid-Derivat von AmlodipinInfo
- Publication number
- DE20115218U1 DE20115218U1 DE20115218U DE20115218U DE20115218U1 DE 20115218 U1 DE20115218 U1 DE 20115218U1 DE 20115218 U DE20115218 U DE 20115218U DE 20115218 U DE20115218 U DE 20115218U DE 20115218 U1 DE20115218 U1 DE 20115218U1
- Authority
- DE
- Germany
- Prior art keywords
- compound
- salt
- formula
- amlodipine
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 Amide derivative of amlodipine Chemical class 0.000 title claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 49
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical group CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 41
- 229960000528 amlodipine Drugs 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 15
- 206010002383 Angina Pectoris Diseases 0.000 claims description 10
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 10
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 8
- 239000011976 maleic acid Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003377 acid catalyst Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 5
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002841 Lewis acid Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000007517 lewis acids Chemical group 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 description 6
- 239000000480 calcium channel blocker Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000007112 amidation reaction Methods 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 201000001068 Prinzmetal angina Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- NCQQYEAGTDFDQX-KTKRTIGZSA-N (z)-4-[2-[[4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxy]ethylamino]-4-oxobut-2-enoic acid Chemical compound CCOC(=O)C1=C(COCCNC(=O)\C=C/C(O)=O)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl NCQQYEAGTDFDQX-KTKRTIGZSA-N 0.000 description 1
- BSSNZUFKXJJCBG-UPHRSURJSA-N (z)-but-2-enediamide Chemical compound NC(=O)\C=C/C(N)=O BSSNZUFKXJJCBG-UPHRSURJSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- AHHPZGUFLGCZCF-UHFFFAOYSA-N 3-o-ethyl 5-o-methyl 4-(2-chlorophenyl)-2-[2-(1,3-dioxoisoindol-2-yl)ethoxymethyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(COCCN2C(C3=CC=CC=C3C2=O)=O)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl AHHPZGUFLGCZCF-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000008061 calcium-channel-blocking effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
Microweg 22, 6545 CM Nijmegen, Niederlande
Schmelzpunkt: 83 0C - 86 0C
Reinheit: größer als 95 % (HPLC)
Claims (20)
oder ein pharmazeutisch annehmbares Salz davon.
oder eines pharmazeutisch annehmbaren Salzes davon sowie einen pharmazeutisch annehmbaren Träger.
oder eines Salzes davon, herstellbar durch Umsetzung von Amlodipin oder eines Salzes davon mit einer Carbonyl-aktivierten Maleinsäureverbindung.
oder ein pharmazeutisch annehmbares Salz davon.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25858500P | 2000-12-29 | 2000-12-29 | |
US80934801A | 2001-03-16 | 2001-03-16 | |
BE2001/0708A BE1014451A6 (nl) | 2000-12-29 | 2001-11-05 | Amidederivaat van amlodipine. |
Publications (1)
Publication Number | Publication Date |
---|---|
DE20115218U1 true DE20115218U1 (de) | 2002-01-24 |
Family
ID=29740324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE20115218U Expired - Lifetime DE20115218U1 (de) | 2000-12-29 | 2001-09-14 | Amid-Derivat von Amlodipin |
Country Status (7)
Country | Link |
---|---|
US (2) | US6602893B2 (de) |
EP (1) | EP1309554A1 (de) |
BE (1) | BE1014451A6 (de) |
BR (1) | BR0116554A (de) |
CA (1) | CA2433193C (de) |
DE (1) | DE20115218U1 (de) |
WO (1) | WO2002053541A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002053541A1 (en) * | 2000-12-29 | 2002-07-11 | Pfizer Limited | Amide derivative of amlodipine |
US6653481B2 (en) * | 2000-12-29 | 2003-11-25 | Synthon Bv | Process for making amlodipine |
PT1309555E (pt) * | 2000-12-29 | 2005-10-31 | Pfizer Ltd | Processo para a producao de maleato amlodipina |
MXPA03005882A (es) * | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado amida de amlodipina. |
EP1499592A4 (de) * | 2002-04-13 | 2010-01-13 | Hanlim Pharmaceutical Co Ltd | Amlodipinnicotinat und verfahren zu dessen herstellung |
EP1554246B1 (de) * | 2002-08-27 | 2007-08-22 | Bayer HealthCare AG | Dihydropyridinonderivate als hne-inhibitoren |
EP3960158A1 (de) | 2016-10-07 | 2022-03-02 | Silvergate Pharmaceuticals, Inc. | Amlodipinformulierungen |
EP3773574A4 (de) | 2018-04-11 | 2022-03-02 | Silvergate Pharmaceuticals, Inc. | Amlodipinformulierungen |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
PL140573B1 (en) * | 1982-12-21 | 1987-05-30 | Pfizer | Method of obtaining new dihydropyridine derivatives |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
US4983740A (en) | 1986-08-04 | 1991-01-08 | Adir Et Compagnie | Process for 1,4-dihydropyridine compounds |
GB8710493D0 (en) | 1987-05-02 | 1987-06-03 | Pfizer Ltd | Dihydropyridines |
US5155120A (en) | 1991-01-14 | 1992-10-13 | Pfizer Inc | Method for treating congestive heart failure |
WO1993006082A1 (en) | 1991-09-13 | 1993-04-01 | Merck & Co., Inc. | Process for the preparation of 4-substituted-1,4-dihydropyridines |
US5389654A (en) | 1992-11-26 | 1995-02-14 | Lek, Tovarna, Farmacevtskih In Kemicnih . . . | 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate |
HU221810B1 (hu) | 1997-08-12 | 2003-01-28 | EGIS Gyógyszergyár Rt. | Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei |
ZA9810320B (en) | 1997-11-14 | 2000-05-11 | Gea Farmaceutisk Fabrik As | Process for the preparation of 1,4-dihydropyridines and novel compounds of use for such purpose. |
PL189666B1 (pl) | 1998-04-09 | 2005-09-30 | Adamed Sp Z Oo | Sposób otrzymywania benzenosulfonianu amlodypiny |
GB9812413D0 (en) | 1998-06-10 | 1998-08-05 | Glaxo Group Ltd | Compound and its use |
ES2151850B1 (es) | 1998-10-26 | 2001-08-16 | Esteve Quimica Sa | Intermedio para la sintesis de amlodipino para su obtencion y utilizacion correspondiente. |
GB9827387D0 (en) | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel process |
GB9827431D0 (en) | 1998-12-11 | 1999-02-03 | Smithkline Beecham Plc | Novel compound |
EP1309556B1 (de) * | 2000-12-29 | 2004-11-24 | Pfizer Limited | Amlodipinfumarat |
BR0116552A (pt) * | 2000-12-29 | 2004-02-03 | Pfizer Ltd | Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão |
MXPA03005886A (es) * | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado de aspartato de amlodipina como antagonista del canal de calcio. |
PT1309555E (pt) * | 2000-12-29 | 2005-10-31 | Pfizer Ltd | Processo para a producao de maleato amlodipina |
WO2002053541A1 (en) * | 2000-12-29 | 2002-07-11 | Pfizer Limited | Amide derivative of amlodipine |
EP1346214A2 (de) | 2000-12-29 | 2003-09-24 | Pfizer Limited | Referenzstandards und verfahren zur bestimmung der reinheit oder stabilität von amlodipin-maleat |
GB0114709D0 (en) | 2001-06-15 | 2001-08-08 | Pfizer Ltd | Stabilised formulations of amlodipine maleate |
-
2001
- 2001-08-15 WO PCT/NL2001/000604 patent/WO2002053541A1/en not_active Application Discontinuation
- 2001-08-15 BR BR0116554-2A patent/BR0116554A/pt not_active IP Right Cessation
- 2001-08-15 CA CA002433193A patent/CA2433193C/en not_active Expired - Fee Related
- 2001-08-15 EP EP01972794A patent/EP1309554A1/de not_active Withdrawn
- 2001-08-27 US US09/938,818 patent/US6602893B2/en not_active Expired - Fee Related
- 2001-09-14 DE DE20115218U patent/DE20115218U1/de not_active Expired - Lifetime
- 2001-11-05 BE BE2001/0708A patent/BE1014451A6/nl not_active IP Right Cessation
-
2003
- 2003-05-12 US US10/435,014 patent/US7115638B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BE1014451A6 (nl) | 2003-10-07 |
US6602893B2 (en) | 2003-08-05 |
US7115638B2 (en) | 2006-10-03 |
CA2433193C (en) | 2006-01-31 |
BR0116554A (pt) | 2004-02-03 |
WO2002053541A1 (en) | 2002-07-11 |
US20020123518A1 (en) | 2002-09-05 |
EP1309554A1 (de) | 2003-05-14 |
US20030204093A1 (en) | 2003-10-30 |
CA2433193A1 (en) | 2002-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60112305T2 (de) | Verfahren zur herstellung amlodipinmaleat | |
DE3688827T2 (de) | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. | |
DE3787346T2 (de) | Dihydropyridin-Derivate, ihre Herstellung und ihre Verwendung. | |
DE29724281U1 (de) | 4-Phenylpiperidin-Verbindungen | |
DE20116125U1 (de) | Amlodipinfumarat | |
DE2851435A1 (de) | Substituierte amid-derivate des l- und dl-phenylglycins, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel | |
DE3825962A1 (de) | 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
DE20116723U1 (de) | Amlodipinderivate und Vorstufe davon | |
DE20115218U1 (de) | Amid-Derivat von Amlodipin | |
DE20116170U1 (de) | Aspartatderivat des Amlodipins | |
DE60116514T2 (de) | Amlodipinhemimaleat | |
DE60100207T2 (de) | Verfahren zu Synthese von N-(mercaptoacyl)-aminosäure Derivaten von alfasubstituierte Acrylsäuren an | |
DD297813A5 (de) | Verfahren zur herstellung von dihydropyridinamiden | |
AT5378U1 (de) | Amidderivat von amlodipin | |
DE60107440T2 (de) | Amlodipinfumarat | |
CH675419A5 (de) | ||
DE3303616A1 (de) | Mutterkornalkaloide, verfahren zu deren herstellung sowie diese verbindungen enthaltende pharmazeutische zubereitungen | |
AT5379U1 (de) | Aspartatderivat von amlodipin | |
EP0167068B1 (de) | 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3,5-dicarbonsäure-isopropyl-[2-(3-trifluormethylphenoxy)-ethyl]-ester, mehrere Verfahren zu seiner Herstellung sowie seine Verwendung in Arzneimitteln | |
WO2005051909A1 (de) | Verfahren zur herstellung von {n-[1-(s)-carbalkoxy-3-phenylpropyl]-s-alanyl-2s, 3ar, 7as-octahydroindol-2-carbonsäure}verbindungen | |
AT5462U1 (de) | Verfahren zum herstellen von amlodipinmaleat | |
DE10129119B4 (de) | Kristalline Salze von Benzoylbenzofuran-Derivaten, insbesondere von[2-(4-{1-[2-((S)-sec.-Butoxycarbonylmethyl)-benzofuran-3-carbonyl]-methanoyl}-2,6-diiod-phenoxy)-ethyl]-diethylamino und [2-(4-{1-[(3-Methyl-2-(S)-Butoxycarbonylmethyl)-benzofuran-3-carbonyl]- methanoyl}-2,6-diiodphenoxy)-ethyl]-diethylamino, deren Verwendung und Herstellung sowie diese Salze enthaltende Arzneimittel | |
DE2235915C3 (de) | N-eckige Klammer auf 3-Pyrrolidinyliden-(2'-amino-2,4,6-trijodbenzoyl eckige Klammer zu - aminosäuren, deren Herstellung und Verwendung | |
DE20116391U1 (de) | Amlodipinhemimaleat | |
DD273437A5 (de) | Verfahren zur herstellung von dihydropyridin-derivaten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R207 | Utility model specification |
Effective date: 20020228 |
|
R081 | Change of applicant/patentee |
Owner name: PFIZER LTD., GB Free format text: FORMER OWNER: BIOORGANICS B.V., NIJMEGEN, NL Effective date: 20030313 |
|
R081 | Change of applicant/patentee |
Owner name: PFIZER LTD., GB Free format text: FORMER OWNER: SYNTHON LICENSING, LTD., LUXEMBOURG, LU Effective date: 20030812 |
|
R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20041019 |
|
R151 | Utility model maintained after payment of second maintenance fee after six years |
Effective date: 20070822 |
|
R158 | Lapse of ip right after 8 years |
Effective date: 20100401 |